Variables | n (%) | Mean, Median (min.-max.) | Missing values n(%) | ||
---|---|---|---|---|---|
Age (years) | n.a. | 65.2, 67 (33–87) | 0 (0.0%) | ||
Male gender | 62 (82.7%) | n.a. | 0 (0.0%) | ||
Preoperative biliary stent | 58 (77.3%) | n.a. | 5 (6.7%) | ||
Extent of surgery | Local bile duct excision w/o hilus | 1 point | 7 (9.3%) | 3.0, 3 (1–5) | 0 (0.0%) |
Local bile duct excision with hilus | 2 points | 3 (4.0%) | |||
Pancreaticoduodenectomy | 3 points | 54 (72.0%) | |||
with hilus resection | 4 points | 5 (6.7%) | |||
with portal vein resection | 5 points | 6 (8.0%) | |||
Duration of operation (min) | n.a. | 238.1, 230 (130–490) | 0 (0.0%) | ||
Grading | G1 | 1 point | 2 (2.7%) | 2.3, 2 (1–3) | 0 (0.0%) |
G2 | 2 points | 51 (68.0%) | |||
G3 | 3 points | 22 (29.3%) | |||
pT stages | pT1 | 1 point | 4 (5.3%) | 2.6, 3 (1–4) | 0 (0.0%) |
pT2 | 2 points | 28 (37.3%) | |||
pT3 | 3 points | 36 (48%) | |||
pT4 | 4 points | 7 (9.3%) | |||
pN stages | pN0 | 0 points | 34 (45.3%) | 0.6, 1 (0–2) | 0 (0.0%) |
pN1 | 1 point | 39 (52%) | |||
pN2 | 2 point | 2 (2.7%) | |||
M1 stage | 5 (6.7%) | n.a. | 0 (0.0%) | ||
R0 resection | 65 (86.7%) | n.a. | 0 (0.0%) | ||
Perineural invasion | 46 (62.2%) | n.a. | 1 (1.3%) | ||
Venous invasion | 16 (21.6%) | n.a. | 1 (1.3%) | ||
Lymph vessel invasion | 22 (29.7%) | n.a. | 1 (1.3%) | ||
UICC stages | UICC Ia | 1 point | 4 (5.3%) | 3.6, 4 (1–6) | 0 (0.0%) |
UICC Ib | 2 points | 15 (20.0%) | |||
UICC IIa | 3 points | 9 (12.0%) | |||
UICC IIb | 4 points | 32 (42.7%) | |||
UICC III | 5 points | 9 (12.0%) | |||
UICC IV | 6 points | 6 (8.0%) | |||
Grading of complications | Clavien-Dindo Grade 0 | 0 points | 25 (33.3%) | 1.8, 1 (0–5) | 2 (2.7%) |
Clavien-Dindo Grade I | 1 point | 15 (20.0%) | |||
Clavien-Dindo Grade II | 2 points | 7 (9.3%) | |||
Clavien-Dindo Grade III | 3 points | 11 (14.7%) | |||
Clavien-Dindo Grade IV | 4 points | 9 (12.0%) | |||
Clavien-Dindo Grade V | 5 points | 6 (8.0%) | |||
Complications leading to surgical intervention | 19 (26.0%) | n.a. | 2 (2.7%) | ||
Observed overall survival in months | n.a. | 29.1, 19 (0–145) | 2 (2.7%) | ||
Observed disease-free survival in months | n.a. | 20.8, 13 (3–143) | 47 (62.7%) | ||
Hospital mortality | 6 (8.0%) | n.a. | 1 (1.3%) | ||
Hospital stay in days | n.a. | 29.8, 25 (7–102) | 2 (2.7%) | ||
ICU stay in days | n.a. | 7.3, 3 (1–94) | 17 (22.7%) | ||
Days between onset of symptoms and date of surgery | n.a. | 54.9, 34 (8–334) | 36 (48.0%) |